Bi, J.; Dixit, G.; Zhang, Y.; Devor, E.J.; Losh, H.A.; Newtson, A.M.; Coleman, K.L.; Santillan, D.A.; Maretzky, T.; Thiel, K.W.;
et al. Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals 2021, 14, 682.
https://doi.org/10.3390/ph14070682
AMA Style
Bi J, Dixit G, Zhang Y, Devor EJ, Losh HA, Newtson AM, Coleman KL, Santillan DA, Maretzky T, Thiel KW,
et al. Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals. 2021; 14(7):682.
https://doi.org/10.3390/ph14070682
Chicago/Turabian Style
Bi, Jianling, Garima Dixit, Yuping Zhang, Eric J. Devor, Haley A. Losh, Andreea M. Newtson, Kristen L. Coleman, Donna A. Santillan, Thorsten Maretzky, Kristina W. Thiel,
and et al. 2021. "Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy" Pharmaceuticals 14, no. 7: 682.
https://doi.org/10.3390/ph14070682
APA Style
Bi, J., Dixit, G., Zhang, Y., Devor, E. J., Losh, H. A., Newtson, A. M., Coleman, K. L., Santillan, D. A., Maretzky, T., Thiel, K. W., & Leslie, K. K.
(2021). Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals, 14(7), 682.
https://doi.org/10.3390/ph14070682
